UPDATE 1-AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 mln

April 26 (Reuters) - British drugmaker AstraZeneca Plc said on Tuesday Ironwood Pharmaceuticals Inc would buy the U.S. marketing rights for its newly approved gout drug for up to $265 million.